Targeted Disease Treatments: InnoMedica’s Nanotechnology Can Make It Happen.

InnoMedica has already developed a diversified product pipeline based on its liposomal technology platform. All pipeline products build and improve on established active substances with known efficacy profiles, rather than requiring new molecules. Such an approach is interesting from both a medical point of view, as well as regarding entrepreneurial risks and returns. Therapeutic effects of known substances are improved substantially by combining them with the biologically fine-tuned nanocarrier. This approach promises the development of medicines with high chances of translational success, as well as large therapeutic advantages for patients.

Talidox®

This highly effective chemotherapy can convince even in late-stage cancers. Talidox substantially improves the benefit/side-effect profile without causing any serious side-effects. With the safety study already completed, InnoMedica plans to submit its application for market approval to Swissmedic before the end of 2021.

Talineuren®

Fostering regeneration instead of merely preventing degeneration – InnoMedica’s novel and innovative therapeutic approach introduces a paradigm shift to neurology. It promises to revolutionize the therapeutic prognosis for patients with Parkinson’s Disease or Amyotrophic Lateral Sclerosis (ALS). This spring 2021, Talineuren has received an orphan drug designation by the FDA and the EMA for application in ALS.

TaliCoVax19

By developing a vaccine against Covid-19, InnoMedica takes responsibility as a pharmaceutical company and reacts quickly to the volatile pandemic situation thanks to its flexibility, immunological competency, and own manufacturing facility. The biological protein-subunit vaccine promises both good immunisation and tolerance in combination with a rapidly scalable production process.

Product Pipeline

In addition to Talidox (oncology), Talineuren (neurology), and TaliCoVax19 (infectiology), InnoMedica is currently developing a second drug treatment against cancer, a medicine against arteriosclerosis, as well as a contrast agent for marking tumors for more precise surgical removal. Furthermore, InnoMedica is researching a medical solution for combatting resistant bacterial strains in a cooperation project with the University of Bern.

Licensing

InnoMedica’s nano transport system is already in use in first products in oncology, neurology, and infectiology. This technology platform enables the optimization of various types of medicinal agents by improving their efficacy while reducing side effects. InnoMedica is actively examining cooperation with academic and industrial partners.

Pharmaceuticals efficiently targeted

InnoMedica’s nano transport system directly delivers pharmaceutical agents at the source of a disease by encapsulating them in a nanocarrier. InnoMedica’s Talidox delivers an established anti-cancer drug directly in the tumor. The liposomal design of Talineuren even enables bridging the blood-brain barrier for the delivery of a regenerative agent in neurological treatments.

Statements

Statements on Our Work

News

Most Recent Updates

Mai 2021

Interview mit Prof. Dr. Smita Saxena zu Talineuren bei ALS

The application for the first clinical trial with Talineuren, InnoMedica’s drug in the field of neurology, …

Read more

May 2021

Talineuren: Clinical trial application submitted

InnoMedica has reached an important milestone with the submission of the first Clinical Trial Application for …

Read more

March 2021

ODD for Talineuren and capital increase 2021

Both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) approved InnoMedica’s …

Read more